Health AI Central
Share:
Peer-Reviewed Publication
Curr Cardiol Rep2018;20(7):51.May 19, 2018Journal Article

Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.

Parth Shah1
1ObvioHealth, 3452 Lake Lynda Dr., Building 100, Suite 151, Orlando, FL, 32817, USA. prshah06@gmail.com.
PubMed DOI

Abstract

PURPOSE OF REVIEW: This review aims to explore and summarize the current literature on the cardiovascular disease (CVD) healthcare burden and determine the cost-effectiveness of the PCSK9 inhibitors. RECENT FINDINGS: The CVD remain the largest cause of mortality in the USA presenting substantial healthcare cost burden reaching $555 billion in 2016 and projected to rise to $1.1 trillion by 2035. T…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.